![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Aesica Pharmaceuticals Limited Cramlington Gb, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Paroxetine hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2006-096 - Rev 00
This Chemical Type CEP, issued on October 11, 2012, remains in force until May 15, 2023, ensuring its reliability within the pharmaceutical industry.
Substance Number 2283 associated with this CEP further emphasizes